I guess the concept is happy -- the public urging for our world's policy makers to make cancer a top priority -- but the fact that becomes all too apparent on this World Cancer Day is quite sobering. More than seven million people die from cancer and close to 11 million new cases are diagnosed worldwide each year. In 2006, cancer killed more people than AIDS, malaria, and tuberculosis combined.

So today is both happy and sad. But for now, let's focus on the happy.

The Geneva-based International Union Against Cancer (UICC) and member organizations in 86 countries are launching a five-year campaign to impart life lessons to children so they can prevent cancer later in life. Parents are critical in this campaign and must take an active role in teaching their children techniques for saving their lives.

Forty-three percent of cancer cases can be prevented through healthy lifestyles that begin in childhood. The World Cancer Campaign slogan -- Today's Children, Tomorrow's World -- underscores the possibility that a concerted effort among world leaders, parents, and their children can make a real difference through four key actions -- providing a smoke-free environment for children; ensuring children keep physically active, eat a healthy diet, and avoid obesity; educating children about vaccines for virus-related liver and cervical cancers; and limiting children's exposure to the sun.

Former First Lady Barbara Bush, Her Royal Highness Lalla Slama of Morocco, Nigerian President Olusegun Obasanjo, and tennis star Steffi Graf are some of the powerful voices powering this campaign that UICC president Dr. Franco Cavalli says can save so many lives if embraced by those at the highest decision-making levels.

"Complacency and inaction on the part of world community will effectively contribute to more than 10 million deaths every year by 2020," he said.

The world's largest drug maker -- Pfizer Inc. -- announced Monday it will cut 10,000 jobs and close at least five facilities due to fierce competition from generic drug makers. The goal, says Pfizer spokespeople, is to whittle away annual costs by $2 billion by the end of the year -- to combat the prediction that the company will lose 41 percent of its sales to generic drugs between 2010 and 2012.

Pfizer's other obstacles include expiring drug patents -- costing Pfizer about $14 billion in revenues between 2005 and 2007 -- as well as demands for lower prices by insurers and large purchasers, and repeated requests for evidence of products' worth.

The 10,000 layoffs amount to 10 percent of the company's global workforce and will take jobs from 2,200 United States employees. The company will cut 20 percent of its European sales force, will close three research sites in Michigan and two manufacturing plants in New York and Nebraska, and is considering selling a manufacturing site in Germany and closing two research sites in Japan and France. In the midst of all of this, the company will focus its efforts on transforming the way they do business.

"I believe we must transform the way we've done business in the past in order to be more successful in the future," said Jeffrey Kindler, CEO and chairman of Pfizer. " Incremental evolution is not enough. Fundamental change is imperative -- and it must happen now."

Pfizer's Monday announcement is the second declaration of budget cuts. A previous announcement has the company -- the maker of cancer drugs Aromasin, Ellence, Camptosar, and Sutent -- slashing costs by $4 billion a year until 2008.

I have been a cheerleader for the breast cancer drug Herceptin ever since I began receiving it. I had my initial worries -- about an allergic reaction that I knew caused death within 24 hours for a handful of women and about possible toxicity to the heart -- but after faring well through my first dose and having now successfully completed my one year obligation to the drug, with no allergic reaction or heart damage, I have come to believe the Herceptin might just be the gem of a drug that the media says it is. Yet now I've read an article that makes me question what I really know about Herceptin -- and the studies that surround it and the statistics that back it and the messages sent out over the lines of mass communication to every day, non-medical people like me.